NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today previewed its unaudited financial highlights for the fourth quarter ended December 31, 2013.
Revenue in the fourth quarter of 2013 was approximately $1.4 million. This represented the second consecutive quarter of sequential growth from $1.3 million revenue reported for the third quarter of 2013 and $1.2 million revenue reported for the second quarter of 2013.
Help employers find you! Check out all the jobs and post your resume.
